Mounjaro (tirzepatide) is a relatively new medication approved for type 2 diabetes management. It is a once-weekly injectable medication and works as a dual GIP and GLP-1 receptor agonist, which means it affects hormones that regulate blood sugar and appetite. While it shows promising results for glycaemic control and weight management, understanding its side effect profile is crucial for Indian patients considering this treatment option.
Common side effects include nausea, vomiting, diarrhoea, constipation, decreased appetite, and stomach discomfort. These symptoms are typically mild to moderate and often diminish as your body adjusts to the medication.
Read the full article here: https://www.thelondonobesityclinic.co.in/navigating-side-effects-what-indian-patients-should-know-about-mounjaro/
